DrugDashboards

Lorazepam

Lorazepam · LORAZEPAM 2 mg/mL · Injection · Intramuscular; Intravenous · Hikma Pharmaceuticals USA Inc.

NDC 00641-6050-10 · 10 VIAL in 1 CARTON / 10 mL in 1 VIAL · NDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. The price is up 19% over the past year, to $0.6796 per unit. It is in shortage right now — FDA lists the reason as “other”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$2.30per billing unit (2 MG)HCPCS J2060 · Jul 1, 2026
  • Part D plans paid (avg)$40.05per dosage unitgross, before rebates — matched by drug name · 2024
  • List price (WAC, as filed)$106.46per packageHikma Pharmaceuticals USA Inc. · Jun 21, 2023

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.5$1.00Jan 2014May 2017$0.6796
3 price points · per · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$106.46
Reported to Texas DSHS · 2026 annual filing · Hikma Pharmaceuticals USA Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 2 MG
$2.302
HCPCS J2060 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$454
155 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

1.1%chance of a new FDA shortage posting for lorazepam (injectable) in the next 90 days

sterile injectable · price up 94% YoY · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 7× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $9.63 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA018140
TE code
AP
Approval date
Jan 1, 1982
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)Sep 5, 2018
    Other
    month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)Sep 5, 2018
    Demand increase for the drug
    month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)Sep 5, 2018
    Other
    month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)Sep 5, 2018
    Other
    month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)Sep 5, 2018
    Demand increase for the drug
    month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)Sep 5, 2018
    Other
    month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)Sep 5, 2018
    Other
    month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)May 3, 2018
    Demand increase for the drug
    month 101 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)May 3, 2018
    month 101 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)May 3, 2018
    Other
    month 101 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months

Recalls (this NDC)

  • Class II · TerminatedJul 11, 2022
    Hikma Pharmaceuticals USA Inc. — Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

Manufacturers of Lorazepam (Injection)

LabelerStrengthFirst seenLast seen
Hikma Pharmaceuticals USA Inc.LORAZEPAM 2 mg/mLJul 15, 2026Sep 3, 2026
Civica, Inc.LORAZEPAM 2 mg/mLJul 15, 2026Sep 2, 2026
International Medication Systems, LimitedLORAZEPAM 2 mg/mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCLORAZEPAM 2 mg/mLJul 15, 2026Aug 31, 2026
Hikma Pharmaceuticals USA Inc.LORAZEPAM 4 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Lorazepam — NDC 00641-6050-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00641605010.

Free to cite with attribution — see how the data is put together.